Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis
Abstract
Plasma cytokine milieu is abnormal in primary myelofibrosis (PMF) and correlates with disease phenotype and prognosis. In this study, we show that several plasma cytokines are also abnormally expressed in polycythemia vera (PV; n = 65), compared to normal controls ( n = 35), but with a significantly different pattern than that of PMF ( n = 127). Direct phenotypic correlation in PV included levels of IL‐12 with hematocrit; IL‐1b, IL‐2, IL‐7, FGF‐b, and HGF with leukocytosis; and IFN‐α and IFN‐γ with thrombocytosis. In univariate analysis, levels of 13 cytokines (out of 30 analyzed) correlated with survival but only MIP‐1β remained significant on multivariable analysis that included the other cytokines as covariates. Increased level of MIP‐1β ( P < 0.01), older age ( P < 0.01), and leukocytosis ( P = 0.03) maintained their association with shortened survival, on multivariable analysis. This study provides preliminary observations that warrant a larger scale study and suggests the value of plasma cytokines as prognostic biomarkers in PV. Am. J. Hematol., 2012. © 2012 Wiley Periodicals, Inc.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The effects of IFNa on HSCs appear to be genotype-specific, as IFNa frequently induces molecular response in patients with JAK2-mutated MPN but not in those with CALR-mutated MPN.
“However, the effects of IFNa on HSCs appear to be genotypespecific as IFNa frequently induces molecular response in patients with JAK2 -mutated MPN but not in those with CALR -mutated MPN 19 .”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [19]
CALR-mutated MPN rarely demonstrates molecular response to IFNa.
“CALR -mutated MPN rarely demonstrates molecular response 19”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [19]
JAK2-mutated MPN frequently displays clonal stem cell depletion upon IFNa treatment.
“while JAK2 -mutated MPN frequently displays clonal stem cell depletion upon IFNa treatment”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [19]
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115 · see citing works
Type 1 interferon perturbates clonal competition by reshaping human blood development
Lama, C., Isakov, D., Rosenberg, S., Quijada-Álamo, M., Saurty-Seerunghen, M. S., Moein, S., Nozais, M., Abera, T.-A., Sakaguchi, O., Totwani, M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02751-3 · Cited by 3 · see citing works
- Authors
- Vaidya, R., Gangat, N., Jimma, T., Finke, C. M., Lasho, T. L., Pardanani, A., & Tefferi, A.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Tefferi, Ayalew
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2012-09-11
- Volume
- 87
- Issue
- 11
- Pages
- 1003-1005
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2079939446
- Cited by
- 149
- References
- 1
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 9 · 2023: 8 · 2022: 16 · 2021: 24 · 2020: 17 · 2019: 12 · 2018: 9 · 2017: 6 · 2016: 9 · 2015: 11 · 2014: 4 · 2013: 3
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Emergency Medicine › Hematological disorders and diagnostics
- Keywords
- polycythemia vera, plasma cytokines, primary myelofibrosis, prognostic factors, MIP-1β, survival, leukocytosis, thrombocytosis, hematocrit, interferon-alpha, interferon-gamma, IL-12
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Phenotype, Polycythemia Vera, Predictive Value of Tests, Prognosis, Biomarkers, Multivariate Analysis, Proportional Hazards Models, Case-Control Studies, Cytokines, Kaplan-Meier Estimate, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
